Why the study?
NLRP3 inflammasome signaling has been implicated in AF pathophysiology, but its precise role in various cardiac cell types remains poorly understood.
Do therapeutics targeting the NLRP3 inflammasome improve the management of atrial fibrillation?
Design
Review
Key result
Targeting the NLRP3 inflammasome with therapeutics such as colchicine and canakinumab may constitute a novel treatment strategy for the management of atrial fibrillation.
Authors
Loading...
May support NLRP3 inhibition as an AF strategy; leaves open confirmation in prospective trials.
Do therapeutics targeting the NLRP3 inflammasome improve the management of atrial fibrillation?
Targeting the NLRP3 inflammasome with agents like colchicine or canakinumab represents a potential novel therapeutic strategy for the management of atrial fibrillation.
Niskala et al. (2024) conducted a review in Atrial fibrillation. NLRP3 inflammasome targeted therapies (e.g., colchicine, canakinumab) was evaluated. Targeting the NLRP3 inflammasome with therapeutics such as colchicine and canakinumab may constitute a novel treatment strategy for the management of atrial fibrillation.